Living with chronic hepatitis B means managing a long-term infection that requires consistent treatment. For many patients, the ultimate goal is to reach a point where the virus is no longer detectable in the blood. This is measured by a marker called HBsAg.
Researchers looked at 581 patients who were already taking nucleoside analogue therapy. They added peg-interferon to their routine to see if it helped them reach that goal. The results showed that 50 of those patients, or about 8.6 percent, successfully achieved HBsAg loss after their treatment period ended.
While the results show promise, the success rate varies depending on the starting levels of the virus. For example, patients starting with lower levels were more likely to reach the goal than those with very high levels. Because this data comes from a meta-analysis, it provides a broad look at how this combination works for different groups, including both Asian and Caucasian patients.
